Skip to main content
. 2020 Jun 23;33(9):1078–1088. doi: 10.1111/tri.13657

Figure 3.

Figure 3

Competing risk analyses to estimate the cumulative incidence of allograft rejection accounting for death as a competing event for (a) HLA‐AB and (b) HLA‐DR AAMM in all patients; (c) HLA‐AB and (d) HLA‐DR AAMM in split‐level typed patients. Gray test was calculated for group comparisons